News
-
Analytics to boost personalised service
Tuesday | Aug 17 2021AUSTRALIAN Pharmaceutical Industries (API) is partnering with Roy Morgan to use its Helix Personas customer segmentation tool to allow Priceline Pharmacy to deliver a more personalised service.
-
Dispensary Corner 17 Aug 21
Tuesday | Aug 17 2021POLITICS can be a tricky game and getting overly involved can be bad for business, as one pharmacist and activist, Matthew McDonald, discovered the hard way.
-
-
Pharmacy primed for reserve role
Monday | Aug 16 2021AUSTRALIA'S community pharmacy network has the capacity to play a greater role in the rollout of COVID-19 vaccines if needed, Pharmacy Guild of Australia National President, Trent Twomey (pictured), believes.
-
APC urges boost in cultural capability
Monday | Aug 16 2021AUSTRALIAN pharmacy education programs could be enhanced with more "cultural capability" as a key way of reducing health disparities and improving the wellbeing of Indigenous communities, according to a new report from the Australian Pharmacy Council (APC).
-
Sleep easy
Monday | Aug 16 2021WHEN life gets stressful it can be difficult to unwind and find sleep.
-
Advise prescriber of tocilizumab sub
Monday | Aug 16 2021THE Pharmaceutical Benefits Scheme (PBS) has confirmed that section 90 pharmacies can supply approved substitute benefits under the Therapeutic Goods Administration's (TGA's) Serious Scarcity Substitution Instrument (SSSI) for tocilizumab.
-
Breathe better
Monday | Aug 16 2021PHARMACISTS can order Snoreben devices that can reduce nasal congestion, airway obstruction, snoring and dry mouth from wholesalers, Symbion and API.
-
TGA starts CPAP post-market review
Monday | Aug 16 2021THE Therapeutic Goods Administration (TGA) has launched a post-market review of continuous positive airway pressure (CPAP), Bi-Level PAP devices and ventilators on the Australian Register of Therapeutic Goods (ARTG).
-
Irbesartan recall
Monday | Aug 16 2021BRITAIN'S Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a pharmacy-level recall of 25 batches of Irbesartan-containing medicines due to contamination with an impurity that could potentially increase the risk of cancer.
